Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor Clinical Trial
Official title:
Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = >3 months).
The (repeated) use of LAT to ≤ 3 OP lesions with continuation of first-line osimertinib, is endorsed by international guidelines (NCCN, ESMO). In this phase IIb prospective non-randomized observational trial, we want to document the benefit of LAT in this patient cohort. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06102928 -
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
|
N/A | |
| Active, not recruiting |
NCT04619004 -
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT06207292 -
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
|
N/A |